Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1099-1107

  Nohata, Nijiro ^a   Hanazawa, Toyoyuki ^a   Kikkawa, Naoko ^a   Sakurai, Daiju ^a   Sasaki, Keita ^b   Chiyomaru, Takeshi ^c   Kawakami, Kazumori ^c   Yoshino, Hirofumi ^c   Enokida, Hideki ^c   Nakagawa, Masayuki ^c   Okamoto, Yoshitaka ^a   Seki, Naohiko ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Maxillary sinus squamous cell carcinoma; MicroRNA; miR 1; miR 133a; Purine nucleoside phosphorylase; Trans gelin 2; Tumor suppressor

Indexed keywords

MESSENGER RNA; MICRORNA; MIR 1; MIR 133A; PURINE NUCLEOSIDE PHOSPHORYLASE; TRANSGELIN; TRANSGELIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL ASSAY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAXILLARY SINUS SQUAMOUS CELL CARCINOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MAXILLARY SINUS NEOPLASMS; MICROFILAMENT PROTEINS; MICRORNAS; MIDDLE AGED; MUSCLE PROTEINS; NEOPLASM STAGING; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 80053185730     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1096     Document Type: Article

References (39)

1. Million RR and Cassisi NJ: Management of Head and Neck Cancer: A Multidisciplinary Approach. 2nd edition. In: Nasal Vestibule, Nasal Cavity, and Paranasal Sinuses. Parsons JT, Striger SP, Mancuso AA and Million RR (ed.) J.B. Lippincott Company, Philadelphia, pp556-559, 1994.
2. Tiwari R, Hardillo JA, Mehta D, Slotman B, Tobi H, Croonenburg E, Van der Waal I and Snow GB: Squamous cell carcinoma of maxil-lary sinus. Head Neck 22: 164-169, 2000. (Pubitemid 30108703)
3. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W and Calcaterra T: Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 92: 3012-3029, 2001. (Pubitemid 33136196)
4. Konno A, Ishikawa K, Terada N, Numata T, Nagata H and Okamoto Y: Analysis of long-term results of our combination therapy for squamous cell cancer of the maxillary sinus. Acta Otolaryngol (Suppl) 537: 57-66, 1998. (Pubitemid 28545378)
5. Bornholdt J, Hansen J, Steiniche T, Dictor M, Antonsen A, Wolff H, Schlunssen V, Holmila R, Luce D, Vogel U, Husgafvel-Pursiainen K and Wallin H: K-ras mutations in sinonasal cancers in relation to wood dust exposure. BMC Cancer 8: 53, 2008.
6. Luce D, Leclerc A, Begin D, Demers PA, Gerin M, Orlowski E, Kogevinas M, Belli S, Bugel I, Bolm-Audorff U, Brinton LA, Comba P, Hardell L, Hayes RB, Magnani C, Merler E, Preston-Martin S, Vaughan TL, Zheng W and Boffetta P: Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. Cancer Causes Control 13: 147-157, 2002. (Pubitemid 34232312)
7. Holt GR: Sinonasal neoplasms and inhaled air toxics. Otolaryngol Head Neck Surg 111: 12-14, 1994.
8. Zheng W, McLaughlin JK, Chow WH, Chien HT and Blot WJ: Risk factors for cancers of the nasal cavity and paranasal sinuses among white men in the United States. Am J Epidemiol 138: 965-972, 1993. (Pubitemid 24002362)
9. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116: 281-297, 2004.
10. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114, 2008.
11. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
12. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
13. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: miR-145, miR-133a and miR-133b: Tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
14. Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa M: The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 104: 808-818, 2011.
15. Mendell JT: miRiad roles for the miR-17-92 cluster in development and disease. Cell 133: 217-222, 2008.
16. Aqeilan RI, Calin GA and Croce CM: miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220, 2010.
17. Mizoguchi H, Komiyama S, Matsui K, Hamanaka R, Ono M, Kiue A, Kobayashi M, Shimizu N, Welgus HG and Kuwano M: The response to epidermal growth factor of human maxillary tumor cells in terms of tumor growth, invasion and expression of proteinase inhibitors. Int J Cancer 49: 738-743, 1991.
18. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M and Seki N: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125: 345-352, 2009.
19. Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki N: miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer 103: 877-884, 2010.
20. Sugimoto T, Seki N, Shimizu S, Kikkawa N, Tsukada J, Shimada H, Sasaki K, Hanazawa T, Okamoto Y and Hata A: The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. Genes Chromosomes Cancer 48: 132-142, 2009.
21. Nelson KM and Weiss GJ: MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther 7: 3655-3660, 2008.
22. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST and Ghoshal K: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283: 33394-33405, 2008.
23. Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, Qu J and Tu L: MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284: 29596-29604, 2009.
24. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Shozu M, Okamoto T and Seki N: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2: 29-44, 2011.
25. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452, 2007. (Pubitemid 47014466)
26. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A and Raponi M: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9: 374, 2009.
27. Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R and Ignace Wei W: Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 123: 251-257, 2008.
28. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J and Lodish HF: Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 24: 3427-3437, 2010.
29. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N and Nakagawa M: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891, 2010.
30. Prinjha RK, Shapland CE, Hsuan JJ, Totty NF, Mason IJ and Lawson D: Cloning and sequencing of cDNAs encoding the actin cross-linking protein transgelin defines a new family of actin-associated proteins. Cell Motil Cytoskeleton 28: 243-255, 1994. (Pubitemid 24216015)
31. Ito M, Depaz I, Wilce P, Suzuki T, Niwa S and Matsumoto I: Expression of human neuronal protein 22, a novel cytoskeleton-associated protein, was decreased in the anterior cingulate cortex of schizophrenia. Neurosci Lett 378: 125-130, 2005. (Pubitemid 40386857)
32. Lawson D, Harrison M and Shapland C: Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 38: 250-257, 1997. (Pubitemid 27484089)
33. Huang J, Sheng HH, Shen T, Hu YJ, Xiao HS, Zhang Q, Zhang QH and Han ZG: Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett 580: 3571-3581, 2006. (Pubitemid 43902791)
34. Shi YY, Wang HC, Yin YH, Sun WS, Li Y, Zhang CQ, Wang Y, Wang S and Chen WF: Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer 92: 929-934, 2005. (Pubitemid 40462641)
35. Rho JH, Roehrl MH and Wang JY: Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res 8: 5610-5618, 2009.
36. Chen R, Yi EC, Donohoe S, Pan S, Eng J, Cooke K, Crispin DA, Lane Z, Goodlett DR, Bronner MP, Aebersold R and Brentnall TA: Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129: 1187-1197, 2005. (Pubitemid 41446859)
37. Bzowska A, Kulikowska E and Shugar D: Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther 88: 349-425, 2000. (Pubitemid 32406058)
38. Alonso R, Lopez-Guerra M, Upshaw R, Bantia S, Smal C, Bontemps F, Manz C, Mehrling T, Villamor N, Campo E, Montserrat E and Colomer D: Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood 114: 1563-1575, 2009.
39. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V and Ravandi F: Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116: 886-892, 2010.